Hutchison Chi-Med makes progress with surufatinib
By Josh White
Date: Friday 14 Jun 2019
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced on Friday that the independent data monitoring committee (IDMC) of the phase 3 pivotal study of 'surufatinib' in advanced neuroendocrine tumors - extra-pancreatic (SANET-ep) had completed a planned interim analysis.
The AIM-traded firm said the IDMC determined that the study had already met the pre-defined primary endpoint of progression-free survival (PFS), and as a result the study would be stopped.
Chi-Med said it would now arrange for a pre-new drug application (NDA) meeting with the China National Medical Products Administration (NMPA) to discuss the preparation of the NDA for surufatinib for that indication.
"We intend to submit the results of the SANET-ep study for presentation at an upcoming scientific conference."
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN